Genmab — August 2018
-
God morgen.:-)
-
God morgen
-
1111
-
-
BMS added a comparator arm to this trial, now Nivo/Dara vs Nivo https://www.clinicaltrials.gov/ct2/history/NCT03098550?A=21&B=22&C=merged
-
ja det ville være rart, hvis den slags blev suppleret med med fremtidsestimater over kursen. Det siger jo sig selv, at 10 milliarder dollars ikke er decideret indregnet allerede nu, men selvfølgelig er kursen mere eller mindre påvirket af forventninger. Det skal den også gerne være
-
E L: It is not Nivo/Dara vs Nivo. One arm is nivo mono in nsclc. The other arm is combination but different cancers. They stopped recruitment in june after only a year. And now they excluded dara from nsclc. Looks like there is a problem in nsclc. Could also be a problem in the other arm as we don't know how many that have clinical benefit. Doesn't look good.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind